S-(2,1,3-benzothiadiazol-4-yl)-3-oxo-3-[4-(pyridin-4-yl)piperazin-1-yl]propane-1-sulfonamido hydrate

• ChemBase ID: 154562
• Molecular Formular: C18H22N6O4S2
• Molecular Mass: 450.53508
• Monoisotopic Mass: 450.11439521
• SMILES: c1cc2c(c(c1)S(=O)(=O)NCCC(=O)N1CCN(CC1)c1ccncc1)nsn2.O
• Canonical SMILES: O=C(N1CCN(CC1)c1ccncc1)CCNS(=O)(=O)c1cccc2c1nsn2.O
• InChI: InChI=1S/C18H20N6O3S2.H2O/c25-17(24-12-10-23(11-13-24)14-4-7-19-8-5-14)6-9-20-29(26,27)16-3-1-2-15-18(16)22-28-21-15;/h1-5,7-8,20H,6,9-13H2;1H2
• InChIKey: NURHGMDBQMBSQI-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: S-(2,1,3-benzothiadiazol-4-yl)-3-oxo-3-[4-(pyridin-4-yl)piperazin-1-yl]propane-1-sulfonamido hydrate
• IUPAC Traditional name: S-(2,1,3-benzothiadiazol-4-yl)-3-oxo-3-[4-(pyridin-4-yl)piperazin-1-yl]propane-1-sulfonamido hydrate
• Synonyms: CID24768606; ML012; N-(3-oxo-3-(4-(pyridine-4-yl)piperazin-1-yl)propyl)benzo[c][1,2,5]thiadiazole-4-sulfonamide hydrate; N-[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide hydrate; VU0255035 hydrate

Database IDs

• CAS Number: 1135243-19-4(anhydrous)
• MDL Number: MFCD16875440
• PubChem SID: 162248700
• PubChem CID: 71311902

CALCULATED PROPERTIES

• Acid pKa: 9.190108
• H Acceptors: 7
• H Donor: 1
• LogD (pH = 5.5): -0.1604921
• LogD (pH = 7.4): -0.021156615
• Log P: 0.42253295
• Molar Refractivity: 110.3863 cm^3
• Polarizability: 43.346012 Å^3
• Polar Surface Area: 108.39 Å^2
• Rotatable Bonds: 5
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO: >5 mg/mL
• Apperance: yellow powder

Safety Information

• European Hazard Symbols: Harmful (Xn)
• German water hazard class: 3
• Risk Statements: 22-36/37/38
• Safety Statements: 26
• GHS Pictograms: GHS07
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H315-H319-H335
• GHS Precautionary statements: P261-P305 + P351 + P338
• Storage Temperature: -20°C

Product Information

• Purity: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C18H20N6O3S2 · xH2O

DETAILS

Sigma Aldrich - V3765

Biochem/physiol Actions
VU0255035 is the first highly selective antagonist at the orthosteric site of the M1 receptor (75-fold selective for M1 relative to other muscarininc subtypes and devoid of activity at other GPCRs, ion channels, transporters and kinases). There are no highly selective M1 muscarinic receptor antagonists. The existing non-selective drugs do not permit direct evaluation of the role of M1 receptors in CNS fucntions and do not premit therapeutic targeting of M1 receptors in various disease states in which M1 receptors are implicated (epilepsy, Parkinson′s disease, attention and cognitive disorders, dystonia, etc).